STAT June 14, 2024
Good morning. We’ve made it to the end of the week! Let’s keep it short and get straight to the news of the day.
The need-to-know this morning
- Cabaletta Bio presented early data on an experimental CD-19 targeting CAR-T therapy for autoimmune disease at a European rheumatology meeting.
Industry cheers Supreme Court decision on abortion pill
Biopharma leaders applauded the Supreme Court’s ruling yesterday that anti-abortion doctors did not have standing to challenge the FDA’s regulation of the abortion pill mifepristone.
The industry had warned that a decision favoring the plaintiffs could have destabilized the drug approval process. Last year, after a federal judge in Texas suspended the FDA’s approval of mifepristone, hundreds of biopharma executives and leaders...